Results 151 to 160 of about 802,581 (339)

ZSF1 lean rats – How healthy are they?

Animal Models and Experimental Medicine, EarlyView.
This study aimed to examine the health status, specifically the physiology and myocardial, vascular, and skeletal muscle function of lean ZSF1 rats by comparing them to age‐ and sex‐matched Wistar rats. Compared to Wistar controls, ZSF1 lean rats exhibited lower body weight, but showed increased heart, and skeletal muscle mass.
Antje Schauer, Beatrice Vahle, Volker Adams, Axel Linke, Antje Augstein   +4 more
wiley   +1 more source

MEDICAL FEES AT ASSURANCE OFFICES.

Habtamu Nigussie Tassie, W.A. Tassie
openalex   +4 more sources

Dysphagia Medical Treatment by Team Approach Based on 2014 Medical Treatment Fee Revisions

, 2015
Yohei Suzuki
openalex   +1 more source

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

Annals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek, David F. Hanff, Pim J. French, Sarah A. van Dijk, Erik A.C. Wiemer, Olivier C. Manintveld, Martin J. van den Bent, Walter Taal   +7 more
wiley   +1 more source

Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric
Aaron W. Abrams, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie A. Benson, Eva‐Chava M. Bernfeld, Leigh E. Charvet, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Kimberly O'Neill, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, John Rose, Alice Rutatangwa, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, Kristen M. Krysko, on behalf of the US Network of Pediatric MS Centers   +27 more
wiley   +1 more source

Correction: Comparison of facilities with and without additional medical fees for nutrition support team activity during the COVID-19 pandemic. [PDF]

J Pharm Health Care Sci
Futamura A, Koseki T, Iida J, Suzuki A, Muroi N, Myotoku M, Maki H, Mizutani K, Ogino H, Taniguchi Y, Higashi K, Usui M.   +11 more
europepmc   +1 more source

Tenecteplase Versus Alteplase for First‐Pass Reperfusion in Basilar Artery Occlusion Stroke Thrombectomy

Annals of Neurology, EarlyView.
Objective The first‐pass effect (FPE), defined as excellent reperfusion after a single attempt, is associated with improved outcomes in large vessel occlusion stroke. We evaluated whether intravenous tenecteplase (TNK) compared with alteplase (TPA) increases the likelihood of FPE in basilar artery occlusion (BAO).
Dylan N. Wolman, Rahul R. Karamchandani, Sina Hemmer, Tyler M. Bielinski, Nitin Goyal, Jeremy B. Rhoten, Mahesh V. Jayaraman, Christian T. Sidebottom, Bradley A. Gross, Alhamza R. Al‐Bayati, Mohamed F. Doheim, Matthew K. Tobin, Anoop Chinthala, Avi Gajjar, Justin Mascitelli, Matthew R. Webb, Jan‐Karl Burkhardt, Kyle W. Scott, Visish Srinivasan, Daniel Tonetti, Manisha Koneru, David J. Altschul, Dhrumhil Vaishnav, Sumeet Multani, Thana Theofanis, William J. Ares, Je Yeong Sone, Ramin Zand, Sasan Bahrami, Jiang Li, Gary Defilipp, Dale Strong, Radmehr Torabi, Krisztina Moldovan, Clemens M. Schirmer, Alexandra R. Paul, Bradley N. Bohnstedt, Raul G. Nogueira, Philipp Hendrix   +38 more
wiley   +1 more source

Comparison of facilities with and without additional medical fees for nutrition support team activity during the COVID-19 pandemic. [PDF]

J Pharm Health Care Sci
Futamura A, Koseki T, Iida J, Suzuki A, Muroi N, Myotoku M, Maki H, Mizutani K, Ogino H, Taniguchi Y, Higashi K, Usui M.   +11 more
europepmc   +1 more source